CD152 [CTLA-4] (mouse):Fc (mouse) (rec.)
The extracellular domain of mouse CD152 [CTLA-4] (aa 38-160) is fused to the N-terminus of the Fc region of mouse IgG2a.
Binds both CD80 (B7-1) and CD86 (B7-2) with high affinity and inhibits CD28 signaling competitively. Kills the target cell completely.
|Endotoxin Content||<0.06EU/μg protein (LAL test; Lonza).|
Reconstitute at 1mg/ml in sterile water.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference NP_033973.2: CD152 (mouse)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.
- Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995)
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997)
- Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001)
- Recombinant Adenovirus Coexpressing Covalent Peptide/MHC Class II Complex and B7-1: In Vitro and In Vivo Activation of Myelin Basic Protein-Specific T Cells: J. Chen, et al.; J. Immunol. 167, 1297 (2001)
- Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion: A.L. Mellor, et al.; J. Immunol. 171, 1652 (2003)
- Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance: A. Sanchez-Fueyo, et al.; Nat. Immunol. 4, 1093 (2003)
- In Vitro and In Vivo Evaluation of Staphylococcal Superantigen Peptide Antagonists: G. Rajagopalan, et al.; Infect. Immun. v72, 6733 (2004)
- Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis: Y.P. de Jong, et al.; Internat. Immunol. 16, 205 (2004)
- Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase: A.L. Mellor, et al.; Internat. Immunol. 16, 1391 (2004)
- A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity: R. Chakrabarti, et al.; Vaccine 23, 4553 (2005)
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses: M.J. Butte, et al.; Immunity 27, 111 (2007)
- Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86–CD28 interaction: R. Kolly, et al.; Prot. Engin. Des. Sel. 20, 91 (2007)
- Pivotal Advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection: H.-P. Raué & M.K. Slifka; J. Leuk. Biol. 81, 1165 (2007)
- Targeted Cleavage of Signaling Proteins by Caspase 3 Inhibits T Cell Receptor Signaling in Anergic T Cells: I. Puga, et al.; Immunity 29, 193 (2008)
- The Tumor Necrosis Factor-Family Receptor DR3 is Essential for Diverse T-Cell Mediated Inflammatory Diseases: F. Meylan, et al.; Immunity 29, 79 (2008)
- Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-mediated PD-L1/2 muscle gene transfer: S. Adriouch, et al.; Front. Microbiol. 2, 199 (2011)